• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

The Glenmark Pharma counter has moved up 5.64 per cent over the month. Market analysts said the company's topline is expected to grow as the company's pain killer drug molecule GRC 6211, which will enter the phase II trials in Europe, may eventually be out licensed and the company would benefit from a milestone payment.

The Rs 2-face valued stock, which touched its 52-week high on the BSE on Thursday at Rs 727, has also been buzzing as market men expect a possible bonus issue announcement soon. However, the company could not be reached for confirmation of the bonus issue.

The stock, which closed at Rs 702.25 on the BSE, witnessed a total quantity of 2.79 lakh shares traded on the BSE and 3.68 lakh shares on the NSE.

Namrata Gada

More Stories on : Stock Markets | Stocks | Ear to the ground | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
`Low' forms, tipped to intensify into depression

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line